Selection from HEOR Bibliography
| Search criteria | ||||
| Hong Kong |
||||
| Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis | ||||
| Lau E1, Salem A2, Chan JCN1, So WY1, Kong A1, Lamotte M2, Luk A1 | ||||
| 1 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, SAR China 2 IQVIA, Zaventem, Belgium | ||||
| Cost Eff Resour Alloc. 2019 Jul 2;17:13. |
||||
| , Article | ||||
| , Hong Kong | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31303866 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2019 | English | , Cost effectiveness | |
| Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis. | ||||
| Popat S1, Mok T2, Yang JC3, Wu YL4, Lungershausen J5, Stammberger U5, Griebsch I5, Fonseca T6, Paz-Ares L7 | ||||
| 1Royal Marsden Hospital, London, UK. 2State Key Laboratory of Southern China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong. 3National Taiwan University, Taipei, Taiwan. 4Guangdong Lung Cancer Institute, Guangzhou, China. 5Boehringer Ingelheim GmbH, Ingelheim, Germany. 6IMS Health, London, UK. 7Instituto de Biomedicina de Sevilla - IBIS (University Hospital Virgen del RocĂo, US, CSIC), Seville, Spain. | ||||
| Lung Cancer. 2014 Aug;85(2):230-8 |
||||
| , Article | ||||
| , China, Germany, Hong Kong, Spain, Taiwan, UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24929780 | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2014 | English | , Meta analysis | |
| New formulation of travoprost reduces dry eye occurrence and costs in glaucoma patients: model-based results for Hong Kong. | ||||
| Tham C1, Leung C1, Li F1, Gerlier L2, Lamotte M2, Caputo J3, Tan R4 | ||||
| 1 Hong Kong Eye Hospital, Hong Kong 2 IMS Health Consulting EMEA, Vilvoorde, Belgium 3 IMS Health Consulting Asia-Pacific, Singapore 4 ALCON Asia-Pacific, Singapore | ||||
| 5th ISPOR Asia-Pacific Conference, 2012, September 2-4, Taipei, Taiwan |
||||
| , Abstract, Poster | ||||
| , Hong Kong | ||||
| Condition | Year | Language | Analysis type | |
| , Ophthalmology | 2012 | English | , Cost effectiveness | |
| Medical resource use and associated costs in open-angle glaucoma in 10 Asia-pacific countries. | ||||
| Gerlier L1, Lamotte M1, Caputo J2, Tan R3 | ||||
| 1 IMS Health Consulting EMEA, Vilvoorde, Belgium 2 IMS Health Consulting Asia-Pacific, Singapore 3 ALCON, Asia-Pacific, Singapore | ||||
| 5th ISPOR Asia-Pacific Conference, 2012, September 2-4, Taipei, Taiwan |
||||
| , Abstract, Poster | ||||
| , Australia, China, Hong Kong, India, Malaysia, New Zealand, Singapore, South Korea, Taiwan, Thailand | ||||
| Condition | Year | Language | Analysis type | |
| , Ophthalmology | 2012 | English | , Burden of illness | |
| Asthma control and its direct healthcare costs: findings using a derived Asthma Control Test (ACT) score in eight Asia-Pacific areas. | ||||
| Lai CKW1 Kuo S-H2 de Guia T3 Lloyd A4, Williams AE5, Spencer MD5 | ||||
| 1 Dept of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong 2 National Taiwan University Hospital, Taipei, Taiwan 3 Philippine Heart Centre, Quezon City, The Philippines 4 Fourth Hurdle Consulting Ltd, London, UK 5 GlaxoSmithKine R&D, Greenford, UK | ||||
| European Respiratory Review 2006; 15:(98): 24-29 |
||||
| , Manuscript in preparation | ||||
| , China, Hong Kong, Malaysia, Philippines, Singapore, Taiwan, Vietnam | ||||
| Condition | Year | Language | Analysis type | |
| , Respiratory disease | 2006 | English | , Cost of illness | |